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Matthew J. Price, MDSEE PAGE 1005P latelet P2Y12-receptor antagonists reduce ma-jor adverse cardiovascular events after percu-taneous coronary intervention (PCI) and in
acute coronary syndrome (ACS) (1–4). Together with
aspirin, they are the cornerstones of adjunctive med-
ical therapy in these clinical settings. Current Amer-
ican College of Cardiology Foundation/American
Heart Association guidelines provide a class I recom-
mendation for all 3 oral P2Y12 receptor antagonists
(clopidogrel, prasugrel, and ticagrelor) in patients
with ACS treated with PCI, but without preference
for a particular agent (5). It is well established that
clopidogrel’s antiplatelet effect varies considerably
among individuals (6,7) and that patients with higher
levels of on-treatment reactivity (OTR) are at higher
risk of thrombotic events after PCI (8–10). It remains
controversial whether high OTR is itself a modiﬁable
risk factor (11–13). However, elucidation of the mech-
anisms of clopidogrel response variability is clinically
relevant as it may provide insight into the reasons
for treatment failure and inform selection of 1 of
the 3 available oral P2Y12 receptor antagonists in
ACS patients.
Clopidogrel is a prodrug requiring hepatic
conversion into an active metabolite (AM) to exert
its antiplatelet effect (Figure 1). Approximately
85% of absorbed clopidogrel is hydrolyzed by
carboxylesterase-1 to an inactive metabolite; there-
fore, only a fraction of the absorbed prodrug is avail-
able for biotransformation into the AM. This is thought
to occur through a 2-step process mediated by the*Editorials published in the Journal of the American College of Cardiology
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oxidized to 2-oxo-clopidogrel, which is then hydro-
lyzed to a highly labile AM that forms a disulﬁde bond
with the P2Y12 receptor as platelets pass through the
liver (14). The CYP2C19 isoenzyme of CYP450 is
important for both steps. Common genetic poly-
morphisms that reduce CYP2C19 catalytic activity
decrease circulating AM levels, reduce platelet inhi-
bition, and increase the risk of ischemic events
in clopidogrel-treated patients with ACS undergoing
PCI (15). The pronounced effect of CYP2C19 loss-
of-function (LOF) allele carriage on AM levels and
clinical outcomes in ACS has led the U.S. Food and
Drug Administration to include this information
within a boxed warning. Similarly, the U.S. Food and
Drug Administration recommends avoiding concom-
itant use of the proton pump inhibitors omeprazole
and esomeprazole because pharmacokinetic and
pharmacodynamic studies have demonstrated that
they inﬂuence CYP2C19 activity, reducing circulating
clopidogrel AM levels and diminishing its anti-
platelet effect (16,17). However, the etiology of clo-
pidogrel response variability is multifactorial, as
CYP2C19 LOF allele carriage accounts for only 5% to
12% of the overall variability (18–20).Diabetes is another major risk factor for dimin-
ished clopidogrel response, independent of the
CYP2C19 genotype (18,19). To date, the etiology of
this phenomenon has largely been attributed to sys-
temic inﬂammation and insulin resistance, the latter
leading to platelet P2Y12 receptor signaling abnor-
malities (21). In this issue of the Journal, Angiolillo
et al. (22) attempt to clarify the mechanism of clopi-
dogrel response variability in the setting of diabetes
in a small, yet elegant study of 60 diabetic and
nondiabetic subjects with stable coronary disease.
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FIGURE 1 Biotransformation of Clopidogrel Into Its AM
Clopidogrel is a prodrug that requires conversion into an active metabolite (AM) to inhibit the platelet P2Y12 receptor. According to a widely
accepted model, clopidogrel is converted in a 2-step process mediated by cytochrome (CYP) P-450, with the CYP2C19 isoenzyme involved in
both steps. A substantial portion of absorbed clopidogrel is shunted into a dead-end pathway by human carboxylesterase-1. Adapted with
permission from Giusti and Abbate (29).
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1016conﬁrm that, after a 600-mg loading dose of clopi-
dogrel, diabetic subjects have higher OTR levels
than nondiabetic subjects, consistent with previous
studies (18,19). After clopidogrel loading, the peak
AM concentration in diabetics was roughly half that
of nondiabetic subjects. Similarly, the area under the
concentration-time curve (AUC), representing the
average AM concentration over the time period
measured, was w60% lower in the diabetic group. To
put this in perspective, CYP2C19 LOF allele carriage
has been associated with an approximate 30%
reduction in the clopidogrel AM AUC in healthy vol-
unteers (23), and coadministration of clopidogrel and
omeprazole results in roughly a 40% reduction (24).
Ex vivo platelet inhibition induced by escalating
clopidogrel AM doses did not appear to differ greatly
between the diabetic and nondiabetic patients,
implying that differences in P2Y12 receptor signaling
was not a major driver of the diminished antiplatelet
effect of clopidogrel loading observed in the diabetic
subjects. Observations from subjects with stable
coronary artery disease must be cautiously applied to
ACS patients, and CYP2C19 genotyping of the study
population was not performed. Furthermore, the
reason why circulating clopidogrel AM levels appear
reduced in diabetic patients remains unknown. These
shortcomings, however, do not undermine the key
ﬁnding of this study: the impaired antiplatelet effect
of clopidogrel among diabetics is mostly due to the
lack of active drug rather than an inherent problem
with their platelets.
This take-away message has substantial implica-
tions for the care of diabetic patients with unstable
coronary artery disease, whom are at particularlyhigh risk of recurrent cardiovascular events after ACS
and stent thrombosis after PCI. Although the efﬁcacy
of point-of-care platelet reactivity or genetic testing
to guide antiplatelet therapy has not yet been
demonstrated (13), and there are no data linking
speciﬁc clopidogrel AM levels with clinical outcomes,
pharmacokinetic studies form the basis for identi-
fying important drug-drug interactions that enable
prescribers to avoid concomitant drugs that may in-
crease adverse effects (by increasing AM levels) or
diminish the desired effect (by decreasing AM
levels). Angiolillo et al. have deﬁned a similar “drug-
patient” interaction between clopidogrel and dia-
betes, and their ﬁndings should similarly inform
medical decision making. Ticagrelor is a direct-acting
agent that does not require biotransformation into
an AM to exert its antiplatelet effect (25), and dia-
betic status had no signiﬁcant inﬂuence on prasugrel
AM levels according to a pharmacokinetic study
of >1,100 ACS patients (26). In TRITON-TIMI 38
(Trial to Assess Improvement in Therapeutic Out-
comes by Optimizing Platelet Inhibition with
Prasugrel-Thrombolysis In Myocardial Infarction 38),
prasugrel tended to provide a greater reduction in
ischemic events than clopidogrel in diabetic patients
compared with nondiabetic patients with ACS un-
dergoing PCI (27). In PLATO (PLATelet inhibition
and patient Outcomes), irrespective of diabetic sta-
tus, there was a consistent beneﬁt with ticagrelor
over clopidogrel, including reduced mortality (28).
Although these studies were not designed or pow-
ered to demonstrate the efﬁcacy of ticagrelor or
prasugrel in the diabetic subgroup alone, the drug-
patient interaction observed by Angiolillo et al.
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1017with clopidogrel provides further support for the
preferred use of ticagrelor and prasugrel in diabetic
patients with ACS and patients with ACS undergoing
PCI, respectively, as long as the bleeding risk is
acceptable and contraindications are not present.
The safety and efﬁcacy of the newer P2Y12 inhibitors
compared with clopidogrel in diabetic patients un-
dergoing complex, nonurgent PCI deserve evalua-
tion, although the overall ischemic event rates in this
setting are lower than in ACS, and the margin of
beneﬁt will likely be narrower.
Routine use of ticagrelor or prasugrel is neither
feasible nor warranted due to cost, adverse effects,
relative contraindications, potential bleeding, and
other challenges. The negative results of the platelet
function testing trials and the absence of random-
ized trials of genotyping do not preclude clinicians
from practicing medicine artfully by incorporating
predictors of drug response to help them selectoptimal antiplatelet therapy in ACS. Pharmacokinetic
and pharmacodynamic studies, such as the one
by Angiolillo et al., can provide clear signposts for
identifying patients, such as those with diabetes, in
whom clopidogrel may not have its intended effect
and for whom ticagrelor or prasugrel should clearly
be preferred. Clinicians should remember, however,
that intensive P2Y12-receptor inhibition is not a
panacea: diabetes is strongly associated with an
increased risk of ischemic events in ACS, irrespective
of the P2Y12 antagonist used (27,28). In the face of
the growing global diabetes epidemic, optimizing
P2Y12 antagonist therapy will, unfortunately, not be
sufﬁcient to fully address this unmet clinical need.
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